Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30

$1.58−0.08 (-4.82%)

Close on Nov 13, 2026Market cap $561.78MP/E –Yield –

Evotec r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was €37.51M, down 26.2% from the year before. The highest annual figure on record is €76.64M in fiscal 2022.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	€37.51M	-26.2%
FY2024	Dec 31, 2024	€50.86M	-25.8%
FY2023	Dec 31, 2023	€68.53M	-10.6%
FY2022	Dec 31, 2022	€76.64M	+6.2%
FY2021	Dec 31, 2021	€72.20M	+12.9%
FY2020	Dec 31, 2020	€63.95M	+9.4%
FY2019	Dec 31, 2019	€58.43M	–

Where these numbers come from

Parsed from the XBRL in Evotec's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-1 split on Oct 20, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Compare: EVO vs PTGX · EVO vs HCM · EVO vs RARE · EVO vs AAPG · EVO vs TLX

Revenue growth-1.1% · median 15.8%

Operating margin-7.1% · median -64.0%

Company	Revenue	Growth
EVO	€788.37M	-1.1%
RARE	$730.00M	+15.8%
PTGX	$551.69M	+163.7%
HCM	$204.89M	-4.3%
AAPG	–	–
TLX	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 4,553
Auditor: BDO AG Wirtschaftsprufungsgesellschaft
SEC CIK: 1412558

Advertisement
300 × 250

See a number that looks wrong?